Oncotarget Increases Readership by Allowing Paper Publication from Fields Other Than Oncology

IntegraGen recently published a paper on Oncotarget. The paper delves into a study conducted by EPOC confirming the existence of a relationship between anti-EGFR treatment efficacy and miR-31-3p expression. When levels of miR-31-3p expression are analyzed in those with RAS wild-type metastatic colorectal cancer, patients who can benefit from targeted anti-EGFR therapy can be identified. Consequently, clinicians now have additional insights on tailored therapeutic options for their patients. The study also emphasizes the benefits of precision medicine and the use of miR-31-3p expression testing.


To help with managing metastatic colorectal cancer (mCRC), IntegraGen has launched a simple ready-to-use kit for quantifying miR-31-3p expression in tumor samples. The miRpredX 31-3p kit quantifies miR-31-3p expression in formalin-fixed, paraffin-embedded (FFPE) samples. The company had earlier on announced a licensing agreement with CERBA laboratories to develop a lab-developed test for the quantifying miR-31-3p expression.

About Oncotarget

Oncotarget is a free-access multidisciplinary journal which publishes papers online on a weekly basis to avail scientific results quickly to a wide audience. The journal was previously dedicated to oncology publications only but has now opened up to other disciplines to spread its impact further. The journal aims to encourage the use of basic and clinical science to fight disease. Not only does it aim to do this, but it also aims to maximize the impact of research through insightful reviews, while eliminating the border between specialties. Additionally, the online journal will now be publishing papers twice instead of once a week to increase the volume, impact, and quality of work disseminated. All papers accepted for publication in the journal will now be directly linked to paginated issues to be published in PubMed. This is with the objective of increasing the frequency of publications of journals on PubMed while in their permanent form.

SCImago Rankings

At the end of 2016, Oncotarget was ranked among the top 50 oncology journals by SCImago Journal & Country Rank. SCImago ratings take into account citations per document, total citations, self-citations, international collaboration, external cites per document, citable documents, among others. As such, this rating is crucial in showing the impact a journal is having on its readers. Given that Oncotarget has now incorporated other fields apart from oncology in the journal, its impact is expected to increase further.

Clay Siegall Further Supports The Development Of Solutions For Cancer Treatment

Clay Siegall is a clinical scientist who has dedicated his career to developing solutions for the treatment of cancer and other terminal illnesses. As a co-founder of Seattle Genetics, he has helped in the development of the company and the installation of a strong research body, which has in the past one decade managed to come up with new and highly reliable drug pipelines. Seattle Genetics is one of the best performing companies in the healthcare industry and its shares shot up over the past five years due to the development of more drug pipelines and the introduction of the ADC Technology, which is gaining popularity as an option for cancer treatment across the world.

Seattle Genetics prides itself in sponsoring a research team that works on delivering ways of cancer treatment that are devoid of the risks of targeting cells that are not infected. They have been working to ensure all the treatment options they come up with are designed to eliminate the effects of some illnesses without having to induce medication that could potentially destroy neighboring cells. As Clay Siegall cites, the company is projected to record higher returns with their ADC Technology, which was tested and proved to offer all the above benefits. Many specialists prefer using this technology for its reliability and strength in the fight against cancer.

About Clay B. Siegall

Clay B. Siegall is an acclaimed authority in the cancer research industry and this is because of the solutions he has helped to offer to the industry. He has been working with different institutions to propose new methods of cancer treatment as well as championing for the development of drugs for other ailments.

His career is founded on clinical science and research, reason he also founded Seattle Genetics on research and the development of solutions that are reliable and unique. Through his support, the company has increased its partnerships with some of the best research institutes and is on a path towards international placement as the most preferred provider of cancer treatment solutions and technology. Clay Siegall has helped the company to grow since inception in 1998 and as the CEO is looking to leave it at a better position.